Gut microbiota in Graves' disease: mechanisms and clinical implications (narrative review)
This narrative review describes associations between gut dysbiosis and Graves' disease but does not establish causality and provides insufficient interventional data to guide clinical practice.
| Population | Patients with Graves' disease (adults, any sex) and healthy controls; human and preclinical studies |
|---|---|
| Intervention | Characterization and modulation of gut microbiota (probiotics, prebiotics, fecal transplant, diet) |
| Comparator | Healthy controls without autoimmune thyroid disease; comparisons among GD subgroups |
| Outcome | Gut microbiota composition in GD vs. controls; Immunological markers (TRAb, Th17/Treg ratio); Intestinal barrier integrity (tight-junction proteins); Efficacy of probiotics/FMT on clinical GD outcomes; Microbial metabolites (SCFAs, LPS, tryptophan) and thyroid immunity; Microbiota-derived diagnostic biomarkers for GD; Graves' orbitopathy and microbiota |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Gut microbiota composition in GD vs. controls | No pooled effect size reported; narrative direction: reduced SCFA-producers, increased pro-inflammatory taxa in GD | — | Low | — | |
| Immunological markers (TRAb, Th17/Treg ratio) | No quantitative synthesis; association described narratively without effect size or CI | — | Low | — | |
| Intestinal barrier integrity (tight-junction proteins) | Mechanistic in vitro/animal data only; in the human RCT effect size reported | — | Very low | — | |
| Efficacy of probiotics/FMT on clinical GD outcomes | No human RCT data; animal models only; in the effect size with CI available | — | Very low | — | |
| Microbial metabolites (SCFAs, LPS, tryptophan) and thyroid immunity | Mechanistic narrative only; in the pooled human effect size reported | — | Very low | — | |
| Microbiota-derived diagnostic biomarkers for GD | No validated biomarker with sensitivity/specificity/AUC reported; exploratory only | — | Very low | — | |
| Graves' orbitopathy and microbiota | Mentioned as clinical subgroup; in the effect size, in the controlled data reported | — | Very low | — |
Context
Graves' disease is the leading cause of autoimmune hyperthyroidism, with an incidence of 20–30 cases/100,000 inhabitants/year and a marked female predominance (5–6:1). The gut-thyroid axis hypothesis proposes that gut microbial alterations modulate immunological tolerance and contribute to autoimmune pathogenesis. The review synthesizes emerging evidence on this interaction, including potential diagnostic and therapeutic applications of the microbiota.
What the study showed
The review reports consistent dysbiosis in GD patients: reduction of SCFA-producing genera (Lactobacillus, Bifidobacterium, Faecalibacterium prausnitzii) and increase of pro-inflammatory taxa (Bacteroides, Prevotella), although the direction and magnitude vary across primary studies. No pooled data with 95% CI are presented for any outcome. The review describes plausible mechanisms — SCFAs, LPS, tryptophan metabolites, Th17/Treg ratio — but does not quantify their effects in controlled trials. Probiotic and fecal microbiota transplant interventions are discussed exclusively based on animal studies and isolated reports, with no efficacy data in humans with GD.
How it was done
Narrative review (non-systematic, no registered PROSPERO protocol, no explicit search strategy, no formal risk-of-bias assessment). Total number of included studies, formal eligibility criteria, and search period are not specified. Integrates observational studies, animal experiments, and in vitro mechanistic data.
Effect magnitude
No pooled effect size with 95% CI is reported. The review does not conduct meta-analysis; effect sizes from individual primary studies are not quantitatively synthesized.
Risk of bias
Narrative review without systematic methodology — high risk of selection and confirmation bias (AMSTAR-2 not applied by authors). Primary studies on microbiota in GD are heterogeneous in population, sequencing techniques, case definition, and confounding control (diet, smoking, medications, ethnicity). Causality cannot be inferred from cross-sectional or associative data. Potential conflicts of interest not explicitly declared in the analyzed version.
What this study does NOT prove
This study does not prove that dysbiosis causes GD, nor that microbiota modulation improves clinical outcomes in humans. It is not generalizable to specific populations by ethnicity, diet, or disease stage.
In clinical practice
Clinicians should not modify GD treatment protocols based on this review. No randomized controlled trial in humans with GD demonstrates efficacy of microbiota interventions on relevant clinical outcomes (remission, TRAb, recurrence). Microbiota research in GD remains exploratory.
Limitations
Narrative review without systematic methodology — high risk of selection and confirmation bias (AMSTAR-2 not applied by authors). Primary studies on microbiota in GD are heterogeneous in population, sequencing techniques, case definition, and confounding control (diet, smoking, medications, ethnicity). Causality cannot be inferred from cross-sectional or associative data. Potential conflicts of interest not explicitly declared in the analyzed version.
What is still missing
Randomized controlled trials with specific microbiota interventions (probiotics, FMT) in GD patients, using standardized clinical outcomes (TRAb, remission rate, recurrence) and minimum 12-month follow-up.
Technical appendix
Version history
- 1.0 · 2026-10-04 — Auto-generated under Evidence Standard v1.0